H2N2V1, PubMed, Curation, bibRecord, 000104

Rapid strategy for screening by pyrosequencing of influenza virus reassortants--candidates for live attenuated vaccines.

Identifieur interne : 000104 ( PubMed/Curation ); précédent : 000103; suivant : 000105

Rapid strategy for screening by pyrosequencing of influenza virus reassortants--candidates for live attenuated vaccines.

Auteurs : Svetlana V. Shcherbik [États-Unis] ; Nicholas C. Pearce [États-Unis] ; Marnie L. Levine [États-Unis] ; Alexander I. Klimov [États-Unis] ; Julie M. Villanueva [États-Unis] ; Tatiana L. Bousse [États-Unis]

Source :

PloS one [ 1932-6203 ] ; 2014.

RBID : pubmed:24647786

Descripteurs français

English descriptors

KwdEn :
- High-Throughput Nucleotide Sequencing, Humans, Influenza A Virus, H3N2 Subtype (genetics), Influenza A Virus, H3N2 Subtype (immunology), Influenza Vaccines (genetics), Influenza Vaccines (immunology), Reassortant Viruses (genetics), Reassortant Viruses (immunology), Vaccines, Attenuated (immunology).
MESH :
- chemical , genetics : Influenza Vaccines.
- genetics : Influenza A Virus, H3N2 Subtype, Reassortant Viruses.
- immunology : Influenza A Virus, H3N2 Subtype, Influenza Vaccines, Reassortant Viruses, Vaccines, Attenuated.
- High-Throughput Nucleotide Sequencing, Humans.

Abstract

Live attenuated influenza vaccine viruses (LAIVs) can be generated by classical reassortment of gene segments between a cold adapted, temperature sensitive and attenuated Master Donor Virus (MDV) and a seasonal wild-type (wt) virus. The vaccine candidates contain hemagglutinin (HA) and neuraminidase (NA) genes derived from the circulating wt viruses and the remaining six genes derived from the MDV strains. Rapid, efficient selection of the viruses with 6∶2 genome compositions from the large number of genetically different viruses generated during reassortment is essential for the biannual production schedule of vaccine viruses.

DOI: 10.1371/journal.pone.0092580
PubMed: 24647786

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000104

Links to Exploration step

pubmed:24647786

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rapid strategy for screening by pyrosequencing of influenza virus reassortants--candidates for live attenuated vaccines.</title>
<author><name sortKey="Shcherbik, Svetlana V" sort="Shcherbik, Svetlana V" uniqKey="Shcherbik S" first="Svetlana V" last="Shcherbik">Svetlana V. Shcherbik</name>
<affiliation wicri:level="1"><nlm:affiliation>Virology, Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America; Battelle, Atlanta, Georgia, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Virology, Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America; Battelle, Atlanta, Georgia</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Pearce, Nicholas C" sort="Pearce, Nicholas C" uniqKey="Pearce N" first="Nicholas C" last="Pearce">Nicholas C. Pearce</name>
<affiliation wicri:level="1"><nlm:affiliation>Virology, Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America; Battelle, Atlanta, Georgia, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Virology, Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America; Battelle, Atlanta, Georgia</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Levine, Marnie L" sort="Levine, Marnie L" uniqKey="Levine M" first="Marnie L" last="Levine">Marnie L. Levine</name>
<affiliation wicri:level="1"><nlm:affiliation>Virology, Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America; Battelle, Atlanta, Georgia, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Virology, Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America; Battelle, Atlanta, Georgia</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Klimov, Alexander I" sort="Klimov, Alexander I" uniqKey="Klimov A" first="Alexander I" last="Klimov">Alexander I. Klimov</name>
<affiliation wicri:level="1"><nlm:affiliation>Virology, Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Virology, Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Villanueva, Julie M" sort="Villanueva, Julie M" uniqKey="Villanueva J" first="Julie M" last="Villanueva">Julie M. Villanueva</name>
<affiliation wicri:level="1"><nlm:affiliation>Virology, Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Virology, Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Bousse, Tatiana L" sort="Bousse, Tatiana L" uniqKey="Bousse T" first="Tatiana L" last="Bousse">Tatiana L. Bousse</name>
<affiliation wicri:level="1"><nlm:affiliation>Virology, Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Virology, Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:24647786</idno>
<idno type="pmid">24647786</idno>
<idno type="doi">10.1371/journal.pone.0092580</idno>
<idno type="wicri:Area/PubMed/Corpus">000104</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000104</idno>
<idno type="wicri:Area/PubMed/Curation">000104</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000104</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Rapid strategy for screening by pyrosequencing of influenza virus reassortants--candidates for live attenuated vaccines.</title>
<author><name sortKey="Shcherbik, Svetlana V" sort="Shcherbik, Svetlana V" uniqKey="Shcherbik S" first="Svetlana V" last="Shcherbik">Svetlana V. Shcherbik</name>
<affiliation wicri:level="1"><nlm:affiliation>Virology, Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America; Battelle, Atlanta, Georgia, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Virology, Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America; Battelle, Atlanta, Georgia</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Pearce, Nicholas C" sort="Pearce, Nicholas C" uniqKey="Pearce N" first="Nicholas C" last="Pearce">Nicholas C. Pearce</name>
<affiliation wicri:level="1"><nlm:affiliation>Virology, Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America; Battelle, Atlanta, Georgia, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Virology, Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America; Battelle, Atlanta, Georgia</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Levine, Marnie L" sort="Levine, Marnie L" uniqKey="Levine M" first="Marnie L" last="Levine">Marnie L. Levine</name>
<affiliation wicri:level="1"><nlm:affiliation>Virology, Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America; Battelle, Atlanta, Georgia, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Virology, Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America; Battelle, Atlanta, Georgia</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Klimov, Alexander I" sort="Klimov, Alexander I" uniqKey="Klimov A" first="Alexander I" last="Klimov">Alexander I. Klimov</name>
<affiliation wicri:level="1"><nlm:affiliation>Virology, Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Virology, Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Villanueva, Julie M" sort="Villanueva, Julie M" uniqKey="Villanueva J" first="Julie M" last="Villanueva">Julie M. Villanueva</name>
<affiliation wicri:level="1"><nlm:affiliation>Virology, Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Virology, Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Bousse, Tatiana L" sort="Bousse, Tatiana L" uniqKey="Bousse T" first="Tatiana L" last="Bousse">Tatiana L. Bousse</name>
<affiliation wicri:level="1"><nlm:affiliation>Virology, Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Virology, Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">PloS one</title>
<idno type="eISSN">1932-6203</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>High-Throughput Nucleotide Sequencing</term>
<term>Humans</term>
<term>Influenza A Virus, H3N2 Subtype (genetics)</term>
<term>Influenza A Virus, H3N2 Subtype (immunology)</term>
<term>Influenza Vaccines (genetics)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Reassortant Viruses (genetics)</term>
<term>Reassortant Viruses (immunology)</term>
<term>Vaccines, Attenuated (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Humains</term>
<term>Sous-type H3N2 du virus de la grippe A (génétique)</term>
<term>Sous-type H3N2 du virus de la grippe A (immunologie)</term>
<term>Séquençage nucléotidique à haut débit</term>
<term>Vaccins antigrippaux (génétique)</term>
<term>Vaccins antigrippaux (immunologie)</term>
<term>Vaccins atténués (immunologie)</term>
<term>Virus recombinants (génétique)</term>
<term>Virus recombinants (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Influenza A Virus, H3N2 Subtype</term>
<term>Reassortant Viruses</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Sous-type H3N2 du virus de la grippe A</term>
<term>Vaccins antigrippaux</term>
<term>Virus recombinants</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Sous-type H3N2 du virus de la grippe A</term>
<term>Vaccins antigrippaux</term>
<term>Vaccins atténués</term>
<term>Virus recombinants</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H3N2 Subtype</term>
<term>Influenza Vaccines</term>
<term>Reassortant Viruses</term>
<term>Vaccines, Attenuated</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>High-Throughput Nucleotide Sequencing</term>
<term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Humains</term>
<term>Séquençage nucléotidique à haut débit</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Live attenuated influenza vaccine viruses (LAIVs) can be generated by classical reassortment of gene segments between a cold adapted, temperature sensitive and attenuated Master Donor Virus (MDV) and a seasonal wild-type (wt) virus. The vaccine candidates contain hemagglutinin (HA) and neuraminidase (NA) genes derived from the circulating wt viruses and the remaining six genes derived from the MDV strains. Rapid, efficient selection of the viruses with 6∶2 genome compositions from the large number of genetically different viruses generated during reassortment is essential for the biannual production schedule of vaccine viruses.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24647786</PMID>
<DateCompleted><Year>2014</Year>
<Month>11</Month>
<Day>12</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>9</Volume>
<Issue>3</Issue>
<PubDate><Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>PloS one</Title>
<ISOAbbreviation>PLoS ONE</ISOAbbreviation>
</Journal>
<ArticleTitle>Rapid strategy for screening by pyrosequencing of influenza virus reassortants--candidates for live attenuated vaccines.</ArticleTitle>
<Pagination><MedlinePgn>e92580</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0092580</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Live attenuated influenza vaccine viruses (LAIVs) can be generated by classical reassortment of gene segments between a cold adapted, temperature sensitive and attenuated Master Donor Virus (MDV) and a seasonal wild-type (wt) virus. The vaccine candidates contain hemagglutinin (HA) and neuraminidase (NA) genes derived from the circulating wt viruses and the remaining six genes derived from the MDV strains. Rapid, efficient selection of the viruses with 6∶2 genome compositions from the large number of genetically different viruses generated during reassortment is essential for the biannual production schedule of vaccine viruses.</AbstractText>
<AbstractText Label="METHODOLOGY/PRINCIPAL FINDINGS" NlmCategory="RESULTS">This manuscript describes a new approach for the genotypic analysis of LAIV reassortant virus clones based on pyrosequencing. LAIV candidate viruses were created by classical reassortment of seasonal influenza A (H3N2) (A/Victoria/361/2011, A/Ohio/02/2012, A/Texas/50/2012) or influenza A (H7N9) (A/Anhui/1/2013) wt viruses with the MDV A/Leningrad/134/17/57(H2N2). Using strain-specific pyrosequencing assays, mixed gene variations were detected in the allantoic progenies during the cloning procedure. The pyrosequencing analysis also allowed for estimation of the relative abundance of segment variants in mixed populations. This semi-quantitative approach was used for selecting specific clones for the subsequent cloning procedures.</AbstractText>
<AbstractText Label="CONCLUSIONS/SIGNIFICANCE" NlmCategory="CONCLUSIONS">The present study demonstrates that pyrosequencing analysis is a useful technique for rapid and reliable genotyping of reassortants and intermediate clones during the preparation of LAIV candidates, and can expedite the selection of vaccine virus candidates.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shcherbik</LastName>
<ForeName>Svetlana V</ForeName>
<Initials>SV</Initials>
<AffiliationInfo><Affiliation>Virology, Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America; Battelle, Atlanta, Georgia, United States of America.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pearce</LastName>
<ForeName>Nicholas C</ForeName>
<Initials>NC</Initials>
<AffiliationInfo><Affiliation>Virology, Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America; Battelle, Atlanta, Georgia, United States of America.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Levine</LastName>
<ForeName>Marnie L</ForeName>
<Initials>ML</Initials>
<AffiliationInfo><Affiliation>Virology, Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America; Battelle, Atlanta, Georgia, United States of America.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Klimov</LastName>
<ForeName>Alexander I</ForeName>
<Initials>AI</Initials>
<AffiliationInfo><Affiliation>Virology, Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Villanueva</LastName>
<ForeName>Julie M</ForeName>
<Initials>JM</Initials>
<AffiliationInfo><Affiliation>Virology, Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bousse</LastName>
<ForeName>Tatiana L</ForeName>
<Initials>TL</Initials>
<AffiliationInfo><Affiliation>Virology, Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2014</Year>
<Month>03</Month>
<Day>19</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>PLoS One</MedlineTA>
<NlmUniqueID>101285081</NlmUniqueID>
<ISSNLinking>1932-6203</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D059014" MajorTopicYN="N">High-Throughput Nucleotide Sequencing</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053122" MajorTopicYN="N">Influenza A Virus, H3N2 Subtype</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016865" MajorTopicYN="N">Reassortant Viruses</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year>
<Month>10</Month>
<Day>25</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2014</Year>
<Month>02</Month>
<Day>23</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2014</Year>
<Month>3</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2014</Year>
<Month>3</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2014</Year>
<Month>11</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">24647786</ArticleId>
<ArticleId IdType="doi">10.1371/journal.pone.0092580</ArticleId>
<ArticleId IdType="pii">PONE-D-13-43612</ArticleId>
<ArticleId IdType="pmc">PMC3960276</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Clin Chem. 2010 Aug;56(8):1340-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20567024</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Mol Diagn. 2010 Jul;12(4):425-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20431034</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Influenza Other Respir Viruses. 2011 Mar;5(2):67-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21306569</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Microbiol. 2011 Apr;49(4):1307-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21307217</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2011 Jul 1;29 Suppl 1:A40-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21684428</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2011;6(6):e20823</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21695145</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vopr Virusol. 2011 May-Jun;56(3):28-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21786624</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2011;6(8):e23400</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21886790</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2012 Jan;12(1):36-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22032844</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Gen Mikrobiol Virusol. 2011;(4):29-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22312898</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol Methods. 2012 Sep;184(1-2):113-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22659066</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2013 May 16;368(20):1888-97</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23577628</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2013 Jul 25;499(7459):500-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23823727</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Virol. 2013 Sep;58(1):94-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23692962</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2013 Sep 26;501(7468):551-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23842494</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Microbiol. 2012;12:96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22672436</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2002 May 15;20(16):2082-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11972977</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol Methods. 2003 May;109(2):171-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12711060</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2003 Sep 8;21(25-26):3867-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12922121</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Scand J Immunol. 2004 Jan;59(1):1-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14723616</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 1977 Oct;37(1):145-59</Citation>
<ArticleIdList><ArticleId IdType="pubmed">915481</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vopr Virusol. 1977 Jul-Aug;(4):387-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">335659</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 1979 Aug;97(1):190-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">473592</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 1981 Apr;53(Pt 2):215-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7264609</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Acta Virol. 1983 Jul;27(4):311-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6195900</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Immun. 1984 Jun;44(3):730-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6724694</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 1992 Feb;186(2):795-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1733114</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Intern Med. 1992 Oct 15;117(8):625-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1530193</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann N Y Acad Sci. 1993 Jun 23;685:803-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8363288</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 1994 Jan;169(1):68-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8277200</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol Methods. 1995 Mar;52(1-2):41-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7769038</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bull World Health Organ. 1996;74(1):77-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8653819</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol Methods. 1996 Feb;56(2):161-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8882646</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Epidemiol. 1997 Jul;13(5):591-609</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9258574</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Anal Biochem. 1997 Oct 1;252(1):24-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9324937</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ind Med Surg. 1965 Jan;34:53-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14267214</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Virol. 2005 May;33(1):25-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15797362</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2005 Oct 1;366(9492):1175-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16198766</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol Methods. 2006 Jun;134(1-2):154-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16434109</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2006 Nov 17;24(47-48):6859-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17050041</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2006 Nov 1;194 Suppl 2:S111-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17163383</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vopr Virusol. 2007 May-Jun;52(3):16-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17601045</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Zh Mikrobiol Epidemiol Immunobiol. 2007 Nov-Dec;(6):40-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18283733</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol Methods. 2008 Nov;153(2):134-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18725246</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2009 Jan;81(1):16-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18835410</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2009 Jun 18;360(25):2616-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19423871</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chin Med J (Engl). 2009 Dec 5;122(23):2880-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20092795</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol Methods. 2010 May;165(2):133-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19883691</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2011 Jan;89(1):115-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21070812</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000104 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000104 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    H2N2V1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:24647786
   |texte=   Rapid strategy for screening by pyrosequencing of influenza virus reassortants--candidates for live attenuated vaccines.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:24647786" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a H2N2V1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 14 19:59:40 2020. Site generation: Thu Mar 25 15:38:26 2021

	Serveur d'exploration H2N2
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration H2N2

Rapid strategy for screening by pyrosequencing of influenza virus reassortants--candidates for live attenuated vaccines.

Rapid strategy for screening by pyrosequencing of influenza virus reassortants--candidates for live attenuated vaccines.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki